3 (AUC, A, B) , and slope analysis (C, D) of both the initial screen (A, C) and rescreened drugs (B, D). Drugs with difference >1 and p-value <0,05 after Bonferroni correction are indicated in blue. (E) FIJI-based validation growth curves of RPE1 control and RPE1 Ts12 Ts5 cells with and without 10 μM 2379. All data involves at least 3 biological replicates, each with 3 technical replicates. Error bars indicate standard error of the mean (SEM). P-values are calculated in two-sided t-test for AUC, correcting for cell line control. DMSO control curves are shared with Sup. Fig. 1C & Sup. Fig. 3G . (A, B) , and the second half (day 5-8) of the screen (C, D). Both AUC (A, C) and slope analysis (B, D) was used to quantify the data. The log (base 2) of the difference between CIN and control growth curves per drug was plotted against the negative log (base 10) of the p-value. Dashed vertical lines refer to a log difference of +/-0.15. All drugs with log of difference >|0.15|, and p-value <0.05 are plotted; drugs with p-values<0.05 after Bonferroni correction are labeled blue. Chi-squared test. "n" referrers to the number of mitotic events per condition. " # " refers to that the same data is also used in Fig. 2E . 
